Onivyde (irinotecan hydrochloride trihydrate) is a potent and specialized anti-cancer medication used in the treatment of certain types of advanced or metastatic cancers. This chemotherapy drug belongs to a class of medications known as topoisomerase I inhibitors and is specifically indicated for patients with metastatic adenocarcinoma of the pancreas after previous therapy has failed.
Key features and characteristics of Onivyde include:
- Active Ingredient: The active ingredient in Onivyde is irinotecan hydrochloride trihydrate, which is a water-soluble form of irinotecan.
- Mechanism of Action: Onivyde exerts its anti-cancer effects by interfering with the replication and transcription of DNA within cancer cells. It works by inhibiting topoisomerase I, an enzyme responsible for unwinding and repairing DNA. By blocking this enzyme, Onivyde causes DNA damage and prevents the cancer cells from dividing and growing.
- Indications: Onivyde is primarily used for the treatment of metastatic adenocarcinoma of the pancreas that has progressed after prior gemcitabine-based chemotherapy. It is not typically used as a first-line treatment for pancreatic cancer.
- Administration: Onivyde is administered intravenously (IV) by a healthcare professional in a clinical setting such as a hospital or infusion center. The dosing regimen and schedule may vary depending on the individual patient and the specific cancer being treated.
- Adverse Effects: Like many chemotherapy drugs, Onivyde may cause a range of side effects, including nausea, vomiting, diarrhea, fatigue, and a decreased white blood cell count (neutropenia), which can increase the risk of infection. Patients receiving Onivyde are closely monitored for these and other potential side effects.
- Special Precautions: Onivyde should only be used under the supervision of an experienced oncologist. It may not be suitable for all patients, and its use should be carefully considered in light of the potential benefits and risks.
- Combination Therapy: Onivyde is sometimes used in combination with other chemotherapy agents or supportive medications to enhance its effectiveness and manage side effects.
- Patient Education: Patients receiving Onivyde should be educated about the potential side effects, the importance of regular follow-up appointments, and the need for diligent monitoring during treatment.
- Research and Clinical Trials: As of my last knowledge update in September 2021, Onivyde had been the subject of ongoing research and clinical trials to explore its efficacy in different cancer types and treatment settings. New developments and indications may have emerged since then.
It’s important to note that medical information can evolve, and the latest guidance on Onivyde should be obtained from a healthcare provider or a reliable medical source, as there may have been updates or changes in its use or availability after my last knowledge update.
Reviews
There are no reviews yet.